Literature DB >> 30006908

Salvage robotic-assisted radical prostatectomy: oncologic and functional outcomes from two high-volume institutions.

Gabriel Ogaya-Pinies1, Estefania Linares-Espinos2, Eduardo Hernandez-Cardona3, Cathy Jenson3, Xavier Cathelineau4, Rafael Sanchez-Salas4, Vipul Patel3.   

Abstract

INTRODUCTION: While no consensus on the optimal salvage treatment exists, only 3% of these patients will get salvage radical prostatectomies due to the assumed technical challenges of this procedure.
OBJECTIVES: Our goal is to analyze the perioperative, oncologic and functional outcomes of patients undergoing salvage robotic-assisted radical prostatectomy (sRARP) after primary treatment failure.
MATERIALS AND METHODS: Data were prospectively collected and retrospectively reviewed from a combined database of more than 14,800 patients who had undergone RARP. We identified 96 patients who underwent sRARP after RT or ablative techniques. Primary cancer characteristics, surgical data, pathology results, perioperative complications, oncologic and functional outcomes were analyzed.
RESULTS: Sixty-eight patients (70.8%) received some source of RT as a primary treatment. The remaining 28 patients: 18 (18.75%) received cryotherapy, seven (7.92%) HIFU, one electroporation, one microwave and one Tookad. complication was seen in 25 (26%) patients (21 minor and 4 major complications). Anastomotic leak was the most common complication, found in 14 (14.6%) of the cases. No rectal injuries occurred. Fourteen (15%) patients had a biochemical failure after a median follow-up of 14 (IQR 5-24) months. Fifty-five (57.3%) of them self-reported to be pad-free at 12 months. Seventeen (55%) of 31 pre-operative potent patients (SHIM score > 21), were potent with or without the use of PDE5i at 12 months.
CONCLUSIONS: sRARP is a feasible alternative for PCa recurrence. Technically the procedure is challenging and should be performed by experienced PCa surgeons. Major complications are uncommon. Continence and potency recovery is possible, but at lower rates than for non-salvage patients.

Entities:  

Keywords:  Brachyterapy; Complications; Cryotherapy; High-intesity focused ultrasound (HIFU); Prostate cancer recurrence; Radiotherapy; Salvage robotic-assisted radical prostatectomy (sRARP)

Mesh:

Year:  2018        PMID: 30006908     DOI: 10.1007/s00345-018-2406-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  1 in total

Review 1.  Management of biochemically recurrent prostate cancer following local therapy.

Authors:  Michael Kolodziej
Journal:  Am J Manag Care       Date:  2014-12       Impact factor: 2.229

  1 in total
  3 in total

1.  Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study.

Authors:  Romain Clery; Pietro Grande; Thomas Seisen; Aurélien Gobert; Igor Duquesne; Arnauld Villers; Jonathan Olivier; Jean-Christophe Bernhard; Grégoire Robert; Jean Baptiste Beauval; Thomas Prudhomme; Franck Bruyère; Paul Lainé-Caroff; David Waltregny; Bertrand Guillonneau; Daniele Panarello; Alain Ruffion; Hubert De Bayser; Alexandre de La Taille; Morgan Roupret
Journal:  World J Urol       Date:  2019-02-21       Impact factor: 4.226

2.  Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.

Authors:  Alexandar Blazevski; William Gondoputro; Matthijs J Scheltema; Amer Amin; Bart Geboers; Daniela Barreto; Anne-Maree Haynes; Ron Shnier; Warick Delprado; Shikha Agrawal; James E Thompson; Phillip D Stricker
Journal:  BMC Urol       Date:  2022-03-02       Impact factor: 2.264

3.  Nightmares in Salvage Robot-assisted Radical Prostatectomy After Primary Radiation Therapy for Prostate Cancer: A Step by Step Tutorial.

Authors:  Alessandro Marquis; Giancarlo Marra; Giorgio Calleris; Marco Oderda; Gabriele Montefusco; Daniele D'Agate; Rene Sotelo; Prasanna Sooriakumaran; Jochen Walz; Paolo Gontero
Journal:  Eur Urol Open Sci       Date:  2022-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.